Recent Updates
Recently added Catalysts

NNC0487-0111 subcutanous

Phase 2

Type 2 Diabetes (T2D) | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Aug 13, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment448

FDA Designations

No designations recorded

Clinical trial landscape

NNC0487-0111 subcutanous · 1 trial · 1 indication

Phase 2 1
NCT06542874A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesType 2 Diabetes (T2D)
COMPLETED448 Analytics
PHASE2COMPLETED
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Type 2 Diabetes (T2D)
NCT06542874448
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change in HbA1c
From baseline (week 0) to end of treatment (week 36)

percent point

Secondary Endpoints

Relative change in body weight
From baseline (week 0) to end of treatment (week 36)
Change in body weight
From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
From baseline (week 0) to end of treatment (week 36)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Placebo subcutaneousPLACEBO_COMPARATORPlacebo for subcutaneous treatment
NNC0487-0111 subcutaneous dose 1EXPERIMENTALNNC0487-0111 subcutaneous dose 1 treatment
NNC0487-0111 subcutaneous dose 2EXPERIMENTALNNC0487-0111 subcutaneous dose 2 treatment
NNC0487-0111 subcutaneous dose 3EXPERIMENTALNNC0487-0111 subcutaneous dose 3 treatment
NNC0487-0111 subcutaneous dose 4EXPERIMENTALNNC0487-0111 subcutaneous dose 4 treatment
NNC0487-0111 subcutaneous dose 5EXPERIMENTALNNC0487-0111 subcutaneous dose 5 treatment
NNC0487-0111 subcutaneous dose 6EXPERIMENTALNNC0487-0111 subcutaneous dose 6 treatment
Placebo oralPLACEBO_COMPARATORPlacebo for oral treatment
NNC0487-0111 oral dose 1EXPERIMENTALNNC0487-0111 oral dose 1 treatment
NNC0487-0111 oral dose 2EXPERIMENTALNNC0487-0111 oral dose 2 treatment
NNC0487-0111 oral dose 3EXPERIMENTALNNC0487-0111 oral dose 3 treatment

Interventions

NameTypeDescription
NNC0487-0111 subcutanousDRUGNNC0487-0111 administered subcutanously (under the skin)
Placebo (NNC0487-0111 subcutanous)DRUGNNC0487-0111 placebo administered subcutanously (under the skin)
NNC0487-0111 oralDRUGNNC0487-0111 administered orally (in the mouth)
Placebo (NNC0487-0111 oral)DRUGNNC0487-0111 placebo administered orally (in the mouth)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites137

Inclusion Criteria: * Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening. * Stable daily dose(s) greater or equal to 90 days before screening of the following antidiab...

Countries:United StatesBulgariaCroatiaGermanyGreeceHungaryJapanPolandRomaniaSlovakiaSpain
Unlock Eligibility Criteria

Competitive Landscape -Diabetes Complications 6 trials (matched to "Type 2 Diabetes (T2D)")

CompanyTickerTrialsLead PhaseDrugs
FibroBiologics, Inc.FBLG1PHASE1Undisclosed
MiMedx Group, Inc.MDXG2N/AUndisclosed
Integra LifeSciences Holdings CorporationIART1N/AUndisclosed
Organogenesis Holdings, Inc. Class AORGO1N/AUndisclosed
Healthcare Services Group, Inc.HCSG1N/AUndisclosed
Unlock Competitive Intelligence

Frequently asked questions about NNC0487-0111 subcutanous

What is NNC0487-0111 subcutaneous used for in Type 2 Diabetes?

NNC0487-0111 subcutaneous is an investigational small molecule being developed for the treatment of Type 2 Diabetes (T2D). It is designed to lower blood sugar levels in people with this condition. The drug is administered subcutaneously and is currently in Phase 2 clinical development, though it remains investigational and not yet approved.

What does NNC0487-0111 target?

The specific molecular target of NNC0487-0111 is not disclosed in the available information. As a small molecule, it is being studied for its ability to lower blood sugar in patients with Type 2 Diabetes, but the exact biological pathway it acts on has not been publicly detailed.

Who makes NNC0487-0111?

NNC0487-0111 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. Novo Nordisk is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Type 2 Diabetes.

What phase is NNC0487-0111 in?

NNC0487-0111 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is being studied for its ability to lower blood sugar in people with Type 2 Diabetes.

What clinical trials is NNC0487-0111 in?

NNC0487-0111 has been studied in one completed Phase 2 clinical trial, registered under the identifier NCT06542874. This randomized, double-blind, placebo-controlled study enrolled 448 participants with Type 2 Diabetes and evaluated how well different doses of the medicine lower blood sugar. The trial was conducted across multiple countries, including the United States, Japan, and several European nations.

Is NNC0487-0111 the same as any other drug?

No alternative names for NNC0487-0111 have been disclosed in the available information. The drug is identified solely by its development code, NNC0487-0111, and is being investigated by Novo Nordisk for the treatment of Type 2 Diabetes.